J.L. Misset

3.4k citations

41 papers · 2.6k indexed · 1 hit paper · h-index 16

Impact in

Oncology top 2%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
Endocrine and Autonomic Systems top 2%
- Circadian rhythm and melatonin

Papers in

Oncology 21
- Cancer Treatment and Pharmacology 11
- Colorectal Cancer Treatments and Studies 9
Genetics 6
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Françis Lévi Sylvie Giacchetti P. Chollet C. Focan B Perpoint Bruno Coudert N Le Bail Stephen D. Walter
Journals: European Journal of Cancer (8 papers)Annals of Oncology (4 papers)Journal of Clinical Oncology (4 papers)Oncology (1 paper)Advances in experimental medicine and biology (1 paper)
Partner nations: France Belgium United States

In The Last Decade

J.L. Misset

40 papers receiving 2.5k citations

Hit Papers

align trajectories log scale

Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer 2000 · 1.1k citations

Peers

Countries citing papers authored by J.L. Misset

Since Specialization

Citations

This map shows the geographic impact of J.L. Misset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.L. Misset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.L. Misset more than expected).

Fields of papers citing papers by J.L. Misset

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.L. Misset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.L. Misset. The network helps show where J.L. Misset may publish in the future.

Co-authors

The 25 scholars most cited alongside J.L. Misset, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.L. Misset Line = papers co-authored together J.L. Misset links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies Annals of Oncology ·C. Mita, Étienne Chatelut, Mohamed Békradda, P Soulié, Pierre Canal, J.L. Misset, Esteban Cvitkovic, R. Bugat	2003	9
2	Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients Annals of Oncology ·Véronique Dièras, Philippe Bougnoux, Thierry Petit, P. Chollet, Philippe Beuzeboc, Christian Borel, F. Husseini, A Goupil, Pierre Kerbrat, J.L. Misset, M.A. Bensmaïne, Isabelle Tabah-Fisch, P Pouillart	2002	61
3	Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients Annals of Oncology ·J.L. Misset, P Vennin, P. Chollet, P Pouillart, P. Laplaige, J.L. Frobert, D. Castéra, M. Fabro, Denis Langlois, Enrico Cortesi, Virgil S. Lucas, Érick Gamelin, A. Laadem, Jorge Otero	2001	27
4	Oxaliplatin clinical activity: a review Critical Reviews in Oncology/Hematology ·J.L. Misset, Harry Bleiberg, William Sutherland, Mohamed Békradda, Esteban Cvitkovic	2000	155
5	Imagerie clinique des métastases ostéocondensantes La Revue de Médecine Interne ·D. Buthiau, Éric-Charles Antoine, P Lapresle, B. Wechsler, G. Missenard, J.L. Misset, Jacques Denarnaud, D. Khayat, Jean-Marc Ziza	1999	0
6	Hepatocellular Carcinoma Cell Lines From Diethylnitrosamine Phenobarbital–Treated Rats. Characterization and Sensitivity to Endothall, A Protein Serine/Threonine Phosphatase–2A Inhibitor Hepatology ·Jean Paul Thiery, I Blazsek, Stéphane Legras, Sylvie Marion, M Reynès, A Anjo, René Adam, J.L. Misset	1999	20
7	Continuous delivery of venous 5-fluorpuracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer Anti-Cancer Drugs ·C. Focan, Françis Lévi, F. Kreutz, D Focan-Henrard, J.P. Lobelle, René Adam, B Dallemagne, C Jehaes, S Markiewicz, J Weerts, Henri Bismuth, C Jasmin, J.L. Misset	1999	16
8	A phase I study of the multitargeted antifolate (MTA) (LY 231514) in combination with oxaliplatin (LOHP) in metastatic solid tumors European Journal of Cancer ·P. Fumoleau, Érick Gamelin, J.L. Misset, Suzette Delaloge, Veronique Ripoche, L. Kayitalire	1999	1
9	Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports Annals of Oncology ·Ernesto Wasserman, Anne Myara, François Lokiec, François Goldwasser, F Trivin, M. Mahjoubi, J.L. Misset, Esteban Cvitkovic	1997	146
10	Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells European Journal of Cancer ·Xuhui Liu, I Blazsek, Martine Comisso, Stéphanie Le Gras, S. Marion, Philippe Quittet, A Anjo, Guangsheng Wang, J.L. Misset	1995	92
11	Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: Relationship with mucosal toxicity in patients with cancer Clinical Pharmacology & Therapeutics ·G. Metzger, Claire Massari, Marie‐Christine Etienne, Martine Comisso, Yvan Touitou, G. Milano, Gérard Bastian, J.L. Misset, Francis Lévi	1994	56
12	Treatment of AIDS-associated Kaposi’s sarcoma with oral tretinoin American Journal of Health-System Pharmacy ·Laurence Bonhomme‐Faivre, G Fredj, E Ecstein, Gilbert Maurisson, C Farabos, J.L. Misset, C Jasmin	1994	8
13	Implications of Chronobiology for 5-Fluorouracil (5-Fu) Efficacy Advances in experimental medicine and biology ·Françis Lévi, S. Brienza, G. Metzer, Petra Deprés-Brummer, F. Bertheault-Cvitkovic, Rachid Zidani, René Adam, J.L. Misset	1993	2
14	[Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS]. PubMed ·G Fredj, F Dietlin, Georges Barbier, C Jasmin, (unknown), S Esctein, J.L. Misset, P Meyer, Dan Kalifa, T Beugre	1993	1
15	Neurotoxicite (NTX) of long term oxaliplatin (L-ORP) therapy European Journal of Cancer ·S. Brienza, J Gastiaburu, Abderrahim Fandi, F. Hugret, M. Itzhaki, S. Lecouturier, Petra Deprés-Brummer, J.L. Misset, Fabio Levi	1993	2
16	Phase I Trial of Recombinant Interleukin-2 Followed by Recombinant Tumor Necrosis Factor in Patients with Metastatic Cancer Journal of Immunotherapy ·Marie Sylvie Negrier, C. N. Pourreau, Peter Palmer, J.Y. Ranchère, A. Mercatello, Patrice Viens, Didier Blaise, C Jasmin, J.L. Misset, C.R. Franks, D Maraninchi, Thierry Philip	1992	14
17	Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. Journal of Clinical Oncology ·Françis Lévi, Manuel Benavides, C. Chevelle, F Saunier, F. Bailleul, J.L. Misset, C Regensberg, Jean-Michel Vannetzel, Alain Reinberg, G Mathé	1990	102
18	Phase II trial of D-Trp-6-LH-RH in advanced breast cancer European Journal of Cancer and Clinical Oncology ·G Mathé, R. Kelling, M.L. VoVan, J Gastiaburu, G. Prévôt, J.M. Vannetzel, Raymond Despax, C Jasmin, Fabio Levi, M Musset, D. Machover, J.L. Misset	1986	16
19	[An analog of gonadoliberin in the treatment of prostatic carcinoma]. PubMed ·G Mathé, Andrew V. Schally, M.L. Vo Van, J Duchier, J.L. Misset, R Keiling	1984	2
20	Immunothérapie active des leucémies aiguës et des lymphosarcomes leucémiques. Bilar de 10 ans-Etude de 200 cas La Nouvelle presse médicale ·G Mathé, Jeanne Amiel, L Schwarzenberg, M Hayat, P Pouillart, M Schneider, A Cattan, C Jasmin, D Belpomme, Jean Schlumberger, F. de Vassal, M Musset, J.L. Misset	1975	3

About J.L. Misset

J.L. Misset is a scholar working on Oncology, Genetics, Pathology and Forensic Medicine, Reproductive Medicine and Cancer Research, having authored 41 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (9 papers), Chronic Lymphocytic Leukemia Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Prostate Cancer Treatment and Research (4 papers), Ovarian cancer diagnosis and treatment (4 papers), Gastric Cancer Management and Outcomes (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). The work is most often cited by research in Oncology (1.6k citations), Endocrine and Autonomic Systems (334 citations), Hepatology (381 citations), Aging (40 citations) and Pathology and Forensic Medicine (337 citations). J.L. Misset has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Françis Lévi, Sylvie Giacchetti, P. Chollet, C. Focan, B Perpoint, Bruno Coudert, N Le Bail, Stephen D. Walter, D Larregain-Fournier and R. Faggiuolo. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Journal of Clinical Oncology, Oncology and Advances in experimental medicine and biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact